prizloncabtagene autoleucel
Cell therapyexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 22, 2023 (NCT05800977)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD20INHIBITOR
MS4A1 inhibitor
- B-lymphocyte antigen CD19INHIBITOR
CD19 inhibitor
TNFRSF9 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314764 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05800977 | Phase 1/Phase 2 (Phase 2) | Feb 22, 2023 | AbelZeta, Cellular Biomedicine Group Ltd., Jiao Tong University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbelZeta | For profit | 1 | 1 | 1 | 2023 |
| Cellular Biomedicine Group Ltd. | For profit | 1 | 1 | 1 | 2023 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1